__NUXT_JSONP__("/drugs/Lutetium_Lu_177_Rosopatamab_Tetraxetan", (function(a,b,c,d){return {data:[{drug:{slug:b,emaEpar:[],fdaDrugLabel:[],id:b,nciThesaurus:{casRegistry:a,chebiId:a,chemicalFormula:a,definition:"A radioimmunoconjugate consisting of rosopatamab, a humanized monoclonal antibody (MoAb) against the external domain of the prostate-specific membrane antigen (PSMA) that is linked, via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and imaging activity during single-photon emission computerized tomography\u002Fcomputerized tomography (SPECT\u002FCT). Upon administration, lutetium Lu 177 rosopatamab tetraxetan binds to PSMA expressed on certain tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to PSMA-expressing cells. PSMA is overexpressed in the malignant prostate and its metastases.",fdaUniiCode:"JB9647672Z",identifier:"C38701",preferredName:c,semanticType:"Amino Acid, Peptide, or Protein",subclassOf:["C129819","C1511"],synonyms:["177Lu-DOTA-TLX591","DOTA-HUJ-591 LU-177","Lu 177 MOAB J591","Lutetium Lu 177 Monoclonal Antibody J591","Lutetium Lu 177 Rosopatamab",c,"Lutetium Lu 177-DOTA-Rosopatamab","Lutetium Lu 177-DOTA-TLX591","ROSOPATAMAB TETRAXETAN LUTETIUM LU-177"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FLutetium_Lu_177_Rosopatamab_Tetraxetan",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("","Lutetium_Lu_177_Rosopatamab_Tetraxetan","Lutetium Lu 177 Rosopatamab Tetraxetan","2021-10-30T13:39:38.483Z")));